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Résumé en
anglais
UNLABELLED: Glioblastoma (GB) is the most frequent and aggressive tumor of the
central nervous system. There is currently growing interest in proteomic studies of
GB, particularly with the aim of identifying new prognostic or therapeutic response
markers. However, comparisons between different proteomic analyses of GB have
revealed few common differentiated proteins. The types of control samples used to
identify such proteins may in part explain the different results obtained. We
therefore tried to determine which control samples would be most suitable for GB
proteomic studies. We used an isotope-coded protein labeling (ICPL) method
followed by mass spectrometry to reveal and compare the protein patterns of two
commonly used types of control sample: GB peritumoral brain zone samples (PBZ)
from six patients and epilepsy surgery brain samples (EB) pooled from three
patients. The data obtained were processed using AMEN software for network
analysis. We identified 197 non-redundant proteins and 35 of them were
differentially expressed. Among these 35 differentially expressed proteins, six were
over-expressed in PBZ and 29 in EB, showing different proteomic patterns between
the two samples. Surprisingly, EB appeared to display a tumoral-like expression
pattern in comparison to PBZ. In our opinion, PBZ may be more appropriate control
sample for GB proteomic analysis.
BIOLOGICAL SIGNIFICANCE: This manuscript describes an original study in
which we used an isotope-coded protein labeling method followed by mass
spectrometry to identify and compare the protein patterns in two types of sample
commonly used as control for glioblastoma (GB) proteomic analysis: peritumoral
brain zone and brain samples obtained during surgery for epilepsy. The choice of
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